Testing for a gene called ESR1 can show which women with breast cancer would benefit most from oestrogen-blocking drugs, Nature Genetics work suggests. Women with extra copies of the gene, which carries DNA code for an oestrogen receptor, had tumours that were more likely to respond to tamoxifen. >>> Discuss This Story
